Third Harmonic Bio discontinuing its chronic inducible urticaria program after its only asset failed in a phase 1 safety trial paralyzes its clinical pipeline. Shareholders are now waiting on a ...
The Company intends to continue THB335 development activities through the first half of 2025 to prepare for the initiation of a 12-week, placebo-controlled Phase 2 study in CSU by mid-year 2025. Key ...
Management to hold conference call/webcast today Tuesday, February 11, 2025, at 8:00 a.m. EST to discuss clinical results and corporate next steps SAN FRANCISCO, Feb. 11, 2025 (GLOBE NEWSWIRE) -- ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback